Items Tagged ‘Management and Prevention of Bone Complications Supportive Care’

February 25th, 2011

Xgeva Reduces Bone Complications From Prostate Cancer

By

Among men with bone metastases from prostate cancer, Xgeva™ (denosumab) was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial were published in The Lancet. Metastatic cancer refers to cancer that has spread to distant sites in the body. Several types of […]

View full entry

Tags: Management and Prevention of Bone Complications Supportive Care, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Supportive Care


November 30th, 2010

Xgeva Approved for Patients with Bone Metastases

By

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with multiple myeloma or other cancers of the blood. Metastatic cancer refers to cancer that has spread […]

View full entry

Tags: Breast Cancer, Management and Prevention of Bone Complications Supportive Care, Metastatic Breast Cancer, Metastatic Stage IV (D) Prostate Cancer, Prostate Cancer, Supportive Care


February 10th, 2010

Denosumab More Effective Than Zometa in Prostate Cancer Patients with Bone Metastases

By

Among men with bone metastases from prostate cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be submitted for presentation at an upcoming medical meeting. Metastatic cancer refers to cancer that has spread to distant […]

View full entry

Tags: Management and Prevention of Bone Complications Supportive Care, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer